WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients

Hong Zhang, Da-Wei Wang, Gunnar Adell and Xiao-Feng Sun

Linköping University Post Print

N.B.: When citing this work, cite the original article.

Original Publication:
Licensee: BioMed Central http://www.biomedcentral.com/
Postprint available at: Linköping University Electronic Press http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-86661
WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients

Hong Zhang¹, Da-Wei Wang¹,², Gunnar Adell³ and Xiao-Feng Sun⁴*

Abstract

Background: Expression of WRAP53 protein has oncogenic properties and it is up regulated in several types of tumors.

Methods: We examined expression of WRAP53 protein in rectal cancers and analyzed its relationship to the response to preoperative radiotherapy and patient survival. The WRAP53 protein was examined by immunohistochemistry in normal mucosa, primary tumors and lymph node metastases from 143 rectal cancer patients participated in a Swedish clinical trial of preoperative radiotherapy.

Results: Frequency of WRAP53 protein expression was increased in primary rectal cancer compared to the normal mucosa (p < 0.05). In non-radiotherapy group positive WRAP53 in primary tumors (p = 0.03, RR, 3.73, 95% CI, 1.13-11.89) or metastases (p = 0.01, RR, 4.11, 95% CI, 1.25-13.14), was associated with poor prognosis independently of stages and differentiations. In radiotherapy group, positive WRAP53 in the metastasis correlated with better survival (p = 0.04). An interaction analysis showed that the correlations of WRAP53 with the prognostic significance with and without radiotherapy in the metastasis differed (p = 0.01). In the radiotherapy group, expression of WRAP53 in metastases gave a better outcome (p = 0.02, RR, 0.32, 95% CI, 0.13-0.84), and an interaction analysis showed significance between the two groups (p = 0.01).

Conclusion: WRAP53 may be a new biomarker used to predict prognosis and to select suitable patients for preoperative radiotherapy.

Keywords: WRAP53, Radiotherapy, Prognosis, Rectal cancer
WRAP53 knockdown triggers apoptosis of cancer cells [11]. Common variations in WRAP53 (alias WDR79) have been associated with an increased risk for developing breast [12] and ovarian cancer [13]. However, there is no evidence concerning WRAP53 expression in rectal cancers, and its association with radiotherapy response.

In this study, we examined WRAP53 protein in biopsies, and surgical specimens from distant normal mucosa, adjacent normal mucosa, primary tumor and lymph node metastasis from the patients participated in a Swedish rectal cancer clinical trial of preoperative radiotherapy (Uppsala, 1986-11-17, Dnr. 86151) [4].

Methods
Rectal cancer patients
The sample profile of the rectal cancer patients showed in Figure 1. Biopsies (n = 98), distant normal mucosa (n = 118), adjacent normal mucosa (n = 81), primary tumors (n = 143) and lymph nodes metastases (n = 49) were from rectal cancer patients in the Southeast Swedish Health Care region, and they participated in the Swedish Rectal Cancer Clinical Trial of Preoperative Radiotherapy between 1987 and 1990, Radiotherapy, Uppsala, 1986-11-17, Dnr. 86151, [4]. There were 171 cancer patients who were randomised selected from Östergötland region, Sweden in the beginning. However, four patients were excluded due to surgically unresectable (advanced disease), and 24 patients had no available tissue specimen for this study. All patients had given their consent to participate in the study. The distant normal mucosa was histologically free from tumor taken from the distant margin, and 65 of them were matched with their primary tumors (i.e., from the same patients). Adjacent normal mucosa was adjacent to the primary tumor from the same tissue sections. Metastases were from the regional lymph nodes, and 37 of them were matched with their primary tumors. Seventy-eight of the patients received surgery alone and 65 received radiotherapy before surgery. The radiotherapy was given at a total of 25 Gy in 5 fractions before surgery over a median of 6 days (range, 5–12 days). Surgery was performed in a median of 3 days (range, 1–13 days) after radiotherapy. None of the patients received adjuvant chemotherapy before or after surgery, and all patients had locally resectable rectal adenocarcinoma. Mean age of the patients at diagnosis was 67 years (range, 36–86 years). All patients were followed-up, and the median of follow-up was 71 months (mean, 85 months). Other characteristics of the patients and tumors are present in Table 1.

The data for terminal deoxynucleotide transferase-mediated deoxyuridine triphosphate-biotin nick end-labeling (TUNEL) assay [14] and survivin expression by immunohistochemistry [15] were taken from previous studies performed in the same patients at our laboratory.

Immunohistochemistry
Tissue arrays sections (5-µm) were deparaffinized, rehydrated and cooked (0.01M Tris-EDTA, pH 9.0) for 5 minutes, incubated in peroxides block (Dako, Carpinteria, CA), and then washed. Sections were covered with primary antibodies for 30 minutes at room temperature and then washed with PBS. The sections were then covered with secondary antibodies for 30 minutes and washed. Visualization was achieved using diaminobenzidine (Dako).

Table 1 Characteristics of patients and rectal cancers

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Non-radiotherapy</th>
<th>Radiotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>45</td>
<td>40</td>
</tr>
<tr>
<td>Female</td>
<td>33</td>
<td>25</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 67</td>
<td>33</td>
<td>26</td>
</tr>
<tr>
<td>&gt; 67</td>
<td>45</td>
<td>39</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>21</td>
<td>18</td>
</tr>
<tr>
<td>IIA + IIIA + IIIB</td>
<td>39</td>
<td>38</td>
</tr>
<tr>
<td>IIIC + IV</td>
<td>18</td>
<td>14</td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Moderately</td>
<td>55</td>
<td>44</td>
</tr>
<tr>
<td>Poorly</td>
<td>18</td>
<td>17</td>
</tr>
<tr>
<td>Number of tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>68</td>
<td>53</td>
</tr>
<tr>
<td>Multiple*</td>
<td>8</td>
<td>12</td>
</tr>
<tr>
<td>Surgical type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rectal amputation</td>
<td>42</td>
<td>25</td>
</tr>
<tr>
<td>Anterior resection</td>
<td>36</td>
<td>40</td>
</tr>
<tr>
<td>Rectal margin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor free</td>
<td>74</td>
<td>62</td>
</tr>
<tr>
<td>Tumor involved margin</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Distance to anal verge (cm)</td>
<td>7.3</td>
<td>8.6</td>
</tr>
</tbody>
</table>

*Other colorectal cancer or other type of tumor besides the present rectal cancer.
The relationship between the WRAP53 and patients survival was further examined in non-radiotherapy and the radiotherapy group. In non-radiotherapy group, WRAP53 expression in the primary tumors was associated with a worse prognosis in a multivariate analysis including both TNM stage and differentiation (p = 0.03, RR, 3.73, 95% CI, 1.13-11.89) although univariate analysis did not show a significant relationship (p = 0.14, Figure 3C). The patients with positive WRAP53 expression in the metastases had worse prognosis in the non-radiotherapy group in both univariate (p = 0.02, Figure 3D), and multivariate analysis including TNM stage and differentiation (p = 0.01, RR, 4.11, 95% CI,
However, there was no significant correlation between WRAP53 in the primary tumor and survival in the radiotherapy (Figure 3E). Surprisingly, in the metastases with radiotherapy, positive WRAP53 turned out to have better prognosis ($p = 0.04$, Figure 3F) although its prognostic significance was lost in a multivariate analysis including both TNM stage and differentiation ($p = 0.14$). A multivariate interaction analysis showed that the correlations with prognostic significance of WRAP53 expression in the metastases without and with radiotherapy differed significantly ($p = 0.01$). Thus, positive WRAP53 expression is a marker of worse prognosis for the patients without radiotherapy. However, in the radiotherapy group, positive WRAP53 expression in the metastasis showed the opposite correlation to survival and was thus more favorable for those patients.

We further analyzed the impact of radiotherapy on the patients survival based on WRAP53 expression. In WRAP53 negative group of either primary or metastatic tumors, radiotherapy had no prognostic effect ($p > 0.05$, data not shown). In the WRAP53 positive group, radiotherapy did not play a prognostic role in primary tumors ($p = 0.36$, Figure 4A). However, radiotherapy did give a better prognosis in the metastasis in either univariate ($p = 0.02$, Figure 4B) or multivariate analysis including both TNM stage and differentiation ($p = 0.02$, RR, 0.32, 95% CI, 0.13-0.84). A multivariate interaction analysis showed that the correlations with prognostic significance of radiotherapy differed significantly between the patients having positive WRAP53 and the patients with negative WRAP53 in the metastasis ($p = 0.01$). Thus, WRAP53 may be a novel
predictive marker for response to the radiotherapy in patients with metastatic rectal cancer.

We also analyzed whether WRAP53 was related to clinicopathological factors in both the non-radiotherapy and radiotherapy group. In the non-radiotherapy group, among 18 patients having local recurrence, 94% showed WRAP53 positive primary tumors, while in 60 non-local recurrences, 75% had WRAP53 positive primary tumors (p = 0.07). In the radiotherapy group, among 5 patients with non-distant recurrence, 100% showed WRAP53 positive expression, while in 16 patients with distant recurrence, only 56% had positive WRAP53 (p = 0.07).

WRAP53 In relation to apoptosis in rectal cancer
Based on the above results, especially the relationship of WRAP53 with radiotherapy and survival, we asked whether WRAP53 might function through an apoptotic pathway. We first analyzed whether WRAP53 was related to apoptosis and the survivin protein in the primary tumor samples (we had no available data of apoptosis and survivin expression from the lymph node metastasis).

In the radiotherapy group, the WRAP53 expression was positively related to apoptosis (p = 0.04) and negatively correlated to survivin (p = 0.002), namely, the tumors showing positive WRAP53 after radiotherapy, had a higher frequency of apoptosis and low frequency of surviving (data not shown). There was no such evidence in the non-radiotherapy (p > 0.05).

Discussion
To our knowledge, this is the first report concerning WRAP53 expression and its association with prognosis.
in rectal cancer. We found that WRAP53 was increased from normal mucosa to primary rectal cancers. Considering previous reports on oncogenic properties of WRAP53 overexpression of WRAP53 contributes to malignant transformation [11], the enhanced WRAP53 in rectal cancer may be a sign of its involvement in the conversion of normal mucosa into cancer. We did not find statistical difference in WRAP53 expression between primary tumors and metastases, suggesting that the WRAP53 plays such role in the early stage of tumor development (Figure 5A). This exposes WRAP53 as a potential “oncoprotein” in early development of rectal cancer, and a new biomarker for early diagnosis of rectal cancer.

The patient material investigated here is from a Swedish clinical trial of preoperative radiotherapy in rectal cancer patients [4]. Therefore, the 143 rectal cancer samples were divided into two groups; tumors not treated with radiotherapy (n = 78) and tumors treated with radiotherapy (n = 65) in order to analyze the role of WRAP53 in the two groups. In the primary tumors without radiotherapy, positive WRAP53 was related to a higher frequency of local recurrence, and worse survival independently of stage and differentiation. A similar result was shown in the lymph node metastases without radiotherapy. This finding strengthens the role of WRAP53 in rectal cancer and identifies WRAP53 as a poor prognostic marker of primary and metastatic tumors without radiotherapy. Surprisingly, in the metastases with radiotherapy, the opposite relationship was observed. Positive expression of WRAP53 protein in this group turned out to have a lower frequency of distant metastasis and better survival. Radiotherapy of the metastasis reduce WRAP53 to a “critically low level”, thus leading to induction of apoptosis. It is well known that primary and metastatic tumors have different biological and clinical features. The numbers of genes distinguish metastases from primary tumors in colorectal cancer patients [16-19]. Even colon cancer cell lines, for example, KM12C, KM12SM and KM12L4a, with different metastatic potentials displayed different morphological and biological features after the treatments with radiation or drugs [20-22]. Thus, certain genes may be directly involved in primary tumor development whereas others play roles in metastasis. The weakness of this study is a small number of the patients in the each subgroup. It is necessary to confirm the results in a larger cohort of patients with rectal cancer with or without radiotherapy in the future. However, the results may raise a notion that we should not focus only on primary tumors but also on metastases in the identification of biomarkers when selecting patients for more efficient treatments.

The next question is whether the apoptosis pathway is involved in the association of WRAP53 with radiotherapy.
indeed, in rectal cancers with radiotherapy, there was a relationship of positive WRAP53 with increased apoptosis and decreased survivin. Moreover, WRAP53 positive colon cancer cells underwent spontaneous apoptosis upon reduction of WRAP53 expression. WRAP53 knockdown has been reported to result in a significant decrease in p53 mRNA and suppression of p53 induction upon DNA damage [7]. Notably, the survivin expression is negatively regulated by wild-type p53 in the p53-dependent apoptotic pathway [23,24]. As mentioned previously, in the strong expression of WRAP53 in biopsies was reduced in the primary tumors after radiotherapy. This provides a possible mechanism to the effects of radiotherapy on cancer. The curative effect of radiotherapy could partially be due to inactivation/down-regulation of WRAP53 protein, subsequently leading to cells apoptosis and necrosis. Alternatively, the radiotherapy and WRAP53 might have an additive effect to cause cell death (Figure 5B). WRAP53 expression has been connected to prognosis and radiotherapy in head-neck cancer [11]. In agreement with our study, high expression of WRAP53 was a marker for poor prognosis in head-neck cancer. Furthermore, the high levels of WRAP53 were correlated to radio-resistance of the head-neck cells. However, since no metastases of head-neck cancer were described it is difficult to compare our studies.

Conclusions

WRAP53 protein may be a potential “oncoprotein” in rectal cancer development, and involved in induction of apoptosis in response to radiotherapy. We propose WRAP53 as biomarker for selecting suitable patients for preoperative radiotherapy.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

This study was supported by grants from the Swedish Cancer Foundation, Swedish Research Council and the Health Research Council in the South-East of Sweden. The Authors thank Dr. David Hinselwood for linguistic revision. Hong Zhang and Da-Wei Wang contributed equally to this work.

Author details

1Division of Biomedicine, The Systems Biology Research Center, University of Skövde, Skövde, Sweden. 2Department of Stomatology, The Third Hospital of Hebei Medical University, Hebei, China. 3Department of Oncology, Karolinska University Hospital, Karolinska, Sweden. 4Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Science, Linköping University, S-581 85, Linköping, Sweden.

Received: 23 January 2012 Accepted: 13 June 2012

Published: 17 July 2012

References


Cite this article as: Zhang et al: WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients. BMC Cancer 2012 12:294.